Recruiting PHASE4 INTERVENTIONAL 1-arm NCT05806580

Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma

A Single-arm Prospective Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma

Sponsor: Ruijin Hospital

Conditions Relapsed or Refractory B-cell Lymphoma

Interventions Relma-cel

Updated 6 times since 2023 Last updated: Oct 21, 2024 Started: May 1, 2023 Primary completion: May 31, 2027 Completion: Dec 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05806580, this PHASE4 trial focuses on Relapsed or Refractory B-cell Lymphoma and remains actively recruiting participants. Sponsored by Ruijin Hospital, it has been updated 6 times since 2023, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Nov 2024 — Present [monthly]

Recruiting PHASE4
Sep 2024 — Nov 2024 [monthly]

Recruiting PHASE4
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE4
Sep 2023 — Jul 2024 [monthly]

Recruiting PHASE4
Jul 2023 — Sep 2023 [monthly]

Recruiting PHASE4

▶ Show 1 earlier version

May 2023 — Jul 2023 [monthly]

Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ruijin Hospital

Data source: Ruijin Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China